Cargando…
Evaluation of the effect of eltrombopag therapy on the platelet collagen receptor glycoprotein VI (GPVI) expression and soluble GPVI levels in young patients with immune thrombocytopenia
BACKGROUND: Platelet glycoprotein VI (GPVI) receptor is essential for platelet adhesion and aggregation. Eltrombopag is as an effective treatment for chronic immune thrombocytopenia (ITP); yet, its effect on platelet function is not fully characterized. AIM: This prospective study investigated the e...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011314/ https://www.ncbi.nlm.nih.gov/pubmed/36479670 http://dx.doi.org/10.1007/s11239-022-02734-1 |
_version_ | 1784906364035792896 |
---|---|
author | Tantawy, Azza Abdel Gawad Elsherif, Nayera Hazaa Khalil Ebeid, Fatma Soliman El-Gamal, Rasha Abd El-Rahman Ismail, Eman Abdel Rahman Kenny, Mahmoud A. morcos, Michael Botros Elkes |
author_facet | Tantawy, Azza Abdel Gawad Elsherif, Nayera Hazaa Khalil Ebeid, Fatma Soliman El-Gamal, Rasha Abd El-Rahman Ismail, Eman Abdel Rahman Kenny, Mahmoud A. morcos, Michael Botros Elkes |
author_sort | Tantawy, Azza Abdel Gawad |
collection | PubMed |
description | BACKGROUND: Platelet glycoprotein VI (GPVI) receptor is essential for platelet adhesion and aggregation. Eltrombopag is as an effective treatment for chronic immune thrombocytopenia (ITP); yet, its effect on platelet function is not fully characterized. AIM: This prospective study investigated the effect of eltrombopag therapy on platelet function through assessment of GPVI receptor expression and soluble GPVI levels among pediatric patients with persistent or chronic ITP. METHODS: Thirty-six children and adolescents with persistent or chronic ITP were divided equally into two groups either to receive eltrombopag therapy or the standard of care. All patients were followed-up for 12 months with assessment of bleeding score and complete blood count (CBC). Evaluation of GPVI expression using flow cytometry and measurement of its soluble form by ELISA was done at baseline and at 6 months. RESULTS: ITP patients on eltrombopag had significantly lower bleeding score after 6 months of therapy while the quality of life has significantly improved. Platelet count was significantly increased throughout the study. GPVI expression by flow cytometry and soluble GPVI levels were significantly increased after eltrombopag therapy. After 12 months, ITP patients on eltrombopag were able to maintain a good quality of life and low bleeding score. CONCLUSION: Our data suggest that eltrombopag, through its effect on the GPVI receptor expression and its soluble form, might reduce bleeding manifestations and improve the quality of life of chronic and persistent ITP children independent of its effect on the platelet count. |
format | Online Article Text |
id | pubmed-10011314 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-100113142023-03-15 Evaluation of the effect of eltrombopag therapy on the platelet collagen receptor glycoprotein VI (GPVI) expression and soluble GPVI levels in young patients with immune thrombocytopenia Tantawy, Azza Abdel Gawad Elsherif, Nayera Hazaa Khalil Ebeid, Fatma Soliman El-Gamal, Rasha Abd El-Rahman Ismail, Eman Abdel Rahman Kenny, Mahmoud A. morcos, Michael Botros Elkes J Thromb Thrombolysis Article BACKGROUND: Platelet glycoprotein VI (GPVI) receptor is essential for platelet adhesion and aggregation. Eltrombopag is as an effective treatment for chronic immune thrombocytopenia (ITP); yet, its effect on platelet function is not fully characterized. AIM: This prospective study investigated the effect of eltrombopag therapy on platelet function through assessment of GPVI receptor expression and soluble GPVI levels among pediatric patients with persistent or chronic ITP. METHODS: Thirty-six children and adolescents with persistent or chronic ITP were divided equally into two groups either to receive eltrombopag therapy or the standard of care. All patients were followed-up for 12 months with assessment of bleeding score and complete blood count (CBC). Evaluation of GPVI expression using flow cytometry and measurement of its soluble form by ELISA was done at baseline and at 6 months. RESULTS: ITP patients on eltrombopag had significantly lower bleeding score after 6 months of therapy while the quality of life has significantly improved. Platelet count was significantly increased throughout the study. GPVI expression by flow cytometry and soluble GPVI levels were significantly increased after eltrombopag therapy. After 12 months, ITP patients on eltrombopag were able to maintain a good quality of life and low bleeding score. CONCLUSION: Our data suggest that eltrombopag, through its effect on the GPVI receptor expression and its soluble form, might reduce bleeding manifestations and improve the quality of life of chronic and persistent ITP children independent of its effect on the platelet count. Springer US 2022-12-07 2023 /pmc/articles/PMC10011314/ /pubmed/36479670 http://dx.doi.org/10.1007/s11239-022-02734-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Tantawy, Azza Abdel Gawad Elsherif, Nayera Hazaa Khalil Ebeid, Fatma Soliman El-Gamal, Rasha Abd El-Rahman Ismail, Eman Abdel Rahman Kenny, Mahmoud A. morcos, Michael Botros Elkes Evaluation of the effect of eltrombopag therapy on the platelet collagen receptor glycoprotein VI (GPVI) expression and soluble GPVI levels in young patients with immune thrombocytopenia |
title | Evaluation of the effect of eltrombopag therapy on the platelet collagen receptor glycoprotein VI (GPVI) expression and soluble GPVI levels in young patients with immune thrombocytopenia |
title_full | Evaluation of the effect of eltrombopag therapy on the platelet collagen receptor glycoprotein VI (GPVI) expression and soluble GPVI levels in young patients with immune thrombocytopenia |
title_fullStr | Evaluation of the effect of eltrombopag therapy on the platelet collagen receptor glycoprotein VI (GPVI) expression and soluble GPVI levels in young patients with immune thrombocytopenia |
title_full_unstemmed | Evaluation of the effect of eltrombopag therapy on the platelet collagen receptor glycoprotein VI (GPVI) expression and soluble GPVI levels in young patients with immune thrombocytopenia |
title_short | Evaluation of the effect of eltrombopag therapy on the platelet collagen receptor glycoprotein VI (GPVI) expression and soluble GPVI levels in young patients with immune thrombocytopenia |
title_sort | evaluation of the effect of eltrombopag therapy on the platelet collagen receptor glycoprotein vi (gpvi) expression and soluble gpvi levels in young patients with immune thrombocytopenia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011314/ https://www.ncbi.nlm.nih.gov/pubmed/36479670 http://dx.doi.org/10.1007/s11239-022-02734-1 |
work_keys_str_mv | AT tantawyazzaabdelgawad evaluationoftheeffectofeltrombopagtherapyontheplateletcollagenreceptorglycoproteinvigpviexpressionandsolublegpvilevelsinyoungpatientswithimmunethrombocytopenia AT elsherifnayerahazaakhalil evaluationoftheeffectofeltrombopagtherapyontheplateletcollagenreceptorglycoproteinvigpviexpressionandsolublegpvilevelsinyoungpatientswithimmunethrombocytopenia AT ebeidfatmasoliman evaluationoftheeffectofeltrombopagtherapyontheplateletcollagenreceptorglycoproteinvigpviexpressionandsolublegpvilevelsinyoungpatientswithimmunethrombocytopenia AT elgamalrashaabdelrahman evaluationoftheeffectofeltrombopagtherapyontheplateletcollagenreceptorglycoproteinvigpviexpressionandsolublegpvilevelsinyoungpatientswithimmunethrombocytopenia AT ismailemanabdelrahman evaluationoftheeffectofeltrombopagtherapyontheplateletcollagenreceptorglycoproteinvigpviexpressionandsolublegpvilevelsinyoungpatientswithimmunethrombocytopenia AT kennymahmouda evaluationoftheeffectofeltrombopagtherapyontheplateletcollagenreceptorglycoproteinvigpviexpressionandsolublegpvilevelsinyoungpatientswithimmunethrombocytopenia AT morcosmichaelbotroselkes evaluationoftheeffectofeltrombopagtherapyontheplateletcollagenreceptorglycoproteinvigpviexpressionandsolublegpvilevelsinyoungpatientswithimmunethrombocytopenia |